Literature DB >> 22017528

Cutaneous adverse drug reactions to allopurinol: 10 year observational survey of the dermatology department--Cagliari University (Italy).

L Atzori1, A L Pinna, L Mantovani, C Ferreli, M Pau, M Mulargia, N Aste.   

Abstract

BACKGROUND: Allopurinol is extensively prescribed for conditions associated with urate excess, despite being responsible for severe cutaneous adverse drug reactions (ADR).
OBJECTIVE: A cross-sectional survey of allopurinol cases observed at the main Dermatology Department with inpatients facilities in southern Sardinia. (approx 560,836 inhabitants).
MATERIAL AND METHODS: Data collection of all consecutive patients referred for ADR between 2001 and 2010. Causality assessment followed the WHO Collaborating Centre for Drug Monitoring criteria; illness severity score was adopted for toxic epidermal necrolysis (SCORTEN).
RESULTS: Allopurinol was the culprit drug in 84 of 780 cutaneous ADR cases (10.7%; 8.4 cases/year). Mean age was 74 years, 58% of the patients were female, 95% of patients required hospitalization. Clinical forms were maculo-papular eruptions (34 cases), Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (31 cases), vasculitis (six cases), Drug Rash Eosinophilia and Systemic Symptoms (DRESS) (three cases), Acute Generalized Exanthematous Pustolosis (AGEP) (three cases), Pityriasis rosea-like eruption (three cases), lichenoid dermatitis (two cases), fixed drug eruption (one case), erythroderma (one case). The indication for allopurinol prescription was asymptomatic hyper-uricemia in 95% of the patients. Twelve patients were under allopurinol dosage adjustment according to creatinine clearance. Final causality assessment was definite for 12% of the cases and probable for the remaining 88%. Full recovery was achieved in 88% of subjects; ten SJS/TEN patients died (12% overall mortality; 32% mortality of the SJS/TEN cases).
CONCLUSION: Considering the populations size of Southern Sardinia, is plausible that 1.5/100,000 Sardinian will be affected by allopurinol related ADR per year. Advanced age, and inappropriate allopurinol prescription were the main conditions affecting morbidity and mortality.
© 2011 The Authors. Journal of the European Academy of Dermatology and Venereology © 2011 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22017528     DOI: 10.1111/j.1468-3083.2011.04313.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  11 in total

Review 1.  Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis.

Authors:  Stefanie Zimmermann; Peggy Sekula; Moritz Venhoff; Edith Motschall; Jochen Knaus; Martin Schumacher; Maja Mockenhaupt
Journal:  JAMA Dermatol       Date:  2017-06-01       Impact factor: 10.282

2.  Flow cytometry test to screen for HLA-B*58:01-associated allopurinol hypersensitivity.

Authors:  Mirko Scarsi; Carla Bosio; Silvia Coccoli; Amilcare Barucco; Giovanna Tavelli; Paolo Airò
Journal:  Clin Rheumatol       Date:  2014-04-13       Impact factor: 2.980

Review 3.  PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.

Authors:  Ellen M McDonagh; Caroline F Thorn; John T Callaghan; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-09       Impact factor: 2.089

4.  Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS/TEN in Thai population.

Authors:  Surasak Saokaew; Wichittra Tassaneeyakul; Ratree Maenthaisong; Nathorn Chaiyakunapruk
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

5.  Genotyping HLA-B*5801 for Allopurinol-Induced Severe Cutaneous Adverse Reactions: An Accurate and Prompt Method.

Authors:  Lin Cheng; Lihua Zhang; Lichen Gao; Wei Zhang; Xiaoping Chen; Hong-Hao Zhou
Journal:  Clin Transl Sci       Date:  2015-12-14       Impact factor: 4.689

6.  The prescription of allopurinol in a tertiary care centre: appropriate indications and dose adjustment.

Authors:  Al-Bishri Jamal; Al-Harthi Salma; Al-Sofiani Wafa; Almutairi Ghadah; Alosaimi Roaa
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2012-05-31

7.  HLA-B*58:01 screening to prevent allopurinol-induced severe cutaneous adverse reactions in Chinese patients with chronic kidney disease.

Authors:  Christina Sze-Man Wong; Chi-Keung Yeung; Chun-Yin Chan; Desmond Yat-Hin Yap; Sydney Chi-Wai Tang; Bernard Man-Yung Cheung; Janette Siu-Yin Kwok; Henry Hin-Lee Chan
Journal:  Arch Dermatol Res       Date:  2021-07-02       Impact factor: 3.033

Review 8.  Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

Authors:  Sheena N Ramasamy; Cameron S Korb-Wells; Diluk R W Kannangara; Myles W H Smith; Nan Wang; Darren M Roberts; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.228

9.  Risk factors for cutaneous reactions to allopurinol in Kinh Vietnamese: results from a case-control study.

Authors:  Minh Duc Do; Thao Phuong Mai; Anh Duy Do; Quang Dinh Nguyen; Nghia Hieu Le; Linh Gia Hoang Le; Vu Anh Hoang; Anh Ngoc Le; Hung Quoc Le; Pascal Richette; Matthieu Resche-Rigon; Thomas Bardin
Journal:  Arthritis Res Ther       Date:  2020-08-03       Impact factor: 5.156

10.  Granulomatous rhinitis secondary to feline leishmaniosis: report of an unusual presentation and therapeutic complications.

Authors:  Rodolfo Oliveira Leal; Hugo Pereira; Clara Cartaxeiro; Esmeralda Delgado; Maria da Conceição Peleteiro; Isabel Pereira da Fonseca
Journal:  JFMS Open Rep       Date:  2018-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.